Proteogenomics of metabolic disease
23 Feb 2024
In this video, Olink® presents proteogenomics of metabolic diseases, an expert-led discussion on the use of proteogenomics in uncovering molecular mechanisms underlying metabolic diseases such as diabetes and obesity. The speakers describe the various proteomic and genomic techniques used in proteogenomics, such as mass spectrometry-based proteomics and bulk and single-cell sequencing, and highlight the advantages and limitations of each approach. They also discuss the challenges associated with proteogenomics, such as the need for sophisticated data analysis and the requirement for high-quality tissue samples.
About the company
Olink Proteomics
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Olink panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Its high-quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.
Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry-leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015.
Following a company reorganization in April, 2016, Olink Proteomics is focusing entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery.
